Insucor

Nebivolol Hydrochloride, the active ingredient in Insucor, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adults. GNH USA supplies Insucor as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is a selective β1‑adrenergic blocker used in cardiovascular disease management.

- Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. - Heart failure: improves left ventricular function and decreases hospitalization rates.

Nebivolol may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness: especially upon standing. - Fatigue: general tiredness. - Nausea: occasional upset stomach. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of ankles.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Heart block: impaired electrical conduction. - Bronchospasm: difficulty breathing, especially in patients with asthma. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzymes. - Hypotension: dangerously low blood pressure.

Before prescribing Nebivolol, clinicians should consider several safety measures.

- Blood pressure monitoring: check regularly to ensure therapeutic control. - Cardiac function assessment: evaluate baseline cardiac status. - Asthma or COPD caution: use with care due to possible bronchoconstriction. - Concomitant beta‑blocker use: avoid additive negative chronotropic effects. - Renal impairment adjustment: dose may need modification in reduced kidney function. - Store at room temperature: keep in original container, protect from moisture.

Nebivolol interacts with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Other β‑blockers: additive negative chronotropic effects. - Calcium channel blockers (verapamil, diltiazem): increased bradycardia risk. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels. - Antiarrhythmic agents (quinidine): enhanced cardiac conduction slowing. - Clonidine withdrawal: may cause rebound hypertension.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect. - ACE inhibitors or ARBs: combined blood pressure lowering. - NSAIDs: may reduce antihypertensive efficacy. - Digoxin: monitor for bradycardia. - Alcohol: can increase dizziness.